RET and medullary thyroid gland carcinoma: Among 319 MTC patients enrolled in the LIBRETTO-001 study, 9 MTC patients harbored p.632_633del RET mutation at exon 11 (c.1894_1899 del GAGCTG), all of whom derived clinical benefit from selpercatinib treatment.